Somatostatin and somatostatin analogues in medullary thyroid carcinoma.
Identifieur interne : 004303 ( Main/Exploration ); précédent : 004302; suivant : 004304Somatostatin and somatostatin analogues in medullary thyroid carcinoma.
Auteurs : RBID : pubmed:8895910English descriptors
- KwdEn :
- Adult, Aged, Antibodies, Monoclonal (diagnostic use), Calcitonin (metabolism), Carcinoembryonic Antigen (metabolism), Carcinoma, Medullary (metabolism), Carcinoma, Medullary (radionuclide imaging), Carcinoma, Medullary (secondary), Female, Humans, Immunoglobulin Fab Fragments (diagnostic use), Indium Radioisotopes (diagnostic use), Male, Middle Aged, Neoplasm Recurrence, Local (radionuclide imaging), Radioimmunodetection, Receptors, Somatostatin (metabolism), Somatostatin (analogs & derivatives), Somatostatin (diagnostic use), Somatostatin (metabolism), Thyroid Neoplasms (metabolism), Thyroid Neoplasms (radionuclide imaging).
- MESH :
- chemical , analogs & derivatives : Somatostatin.
- chemical , diagnostic use : Antibodies, Monoclonal, Immunoglobulin Fab Fragments, Indium Radioisotopes, Somatostatin.
- chemical , metabolism : Calcitonin, Carcinoembryonic Antigen, Receptors, Somatostatin, Somatostatin.
- metabolism : Carcinoma, Medullary, Thyroid Neoplasms.
- radionuclide imaging : Carcinoma, Medullary, Neoplasm Recurrence, Local, Thyroid Neoplasms.
- secondary : Carcinoma, Medullary.
- Adult, Aged, Female, Humans, Male, Middle Aged, Radioimmunodetection.
Abstract
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour characterized by the production and secretion of calcitonin. MTC tumours may express functional somatostatin receptors (hSSTR). A significant proportion of hSSTR receptor-positive MTC tumours, including metastatic disease, may be visualized in vivo through 111In-pentetreotide scintigraphy. Four patients with recurrent/metastatic disease, who had previously been assessed with 111In-anti-CEA monoclonal antibody fragment [F(ab')2] imaging, were evaluated. 111In-pentetreotide scintigraphy localized all known disease sites. Furthermore, mediastinal disease was detected in one patient with negative conventional, and 111In-anti-CEA F(ab')2 imaging studies. The detection of somatostatin within the tumour (2 patients), or negative octreotide challenges (2 patients), did not affect the outcome of 111In-pentetreotide scintigraphy. In conclusion, 111In-pentetreotide scintigraphy appears at least as effective as 111In-anti-CEA F(ab')2 imaging and should be considered in the diagnostic evaluation of MTC, particularly in the setting of recurrent/metastatic disease not detected by conventional means.
PubMed: 8895910
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Somatostatin and somatostatin analogues in medullary thyroid carcinoma.</title><author><name sortKey="O Byrne, K J" uniqKey="O Byrne K">K J O'Byrne</name><affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology, St James's Hospital, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Department of Endocrinology, St James's Hospital, Dublin</wicri:regionArea></affiliation></author><author><name sortKey="O Hare, N" uniqKey="O Hare N">N O'Hare</name></author><author><name sortKey="Sweeney, E" uniqKey="Sweeney E">E Sweeney</name></author><author><name sortKey="Freyne, P J" uniqKey="Freyne P">P J Freyne</name></author><author><name sortKey="Cullen, M J" uniqKey="Cullen M">M J Cullen</name></author></titleStmt><publicationStmt><date when="1996">1996</date><idno type="RBID">pubmed:8895910</idno><idno type="pmid">8895910</idno><idno type="wicri:Area/Main/Corpus">004553</idno><idno type="wicri:Area/Main/Curation">004553</idno><idno type="wicri:Area/Main/Exploration">004303</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal (diagnostic use)</term><term>Calcitonin (metabolism)</term><term>Carcinoembryonic Antigen (metabolism)</term><term>Carcinoma, Medullary (metabolism)</term><term>Carcinoma, Medullary (radionuclide imaging)</term><term>Carcinoma, Medullary (secondary)</term><term>Female</term><term>Humans</term><term>Immunoglobulin Fab Fragments (diagnostic use)</term><term>Indium Radioisotopes (diagnostic use)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (radionuclide imaging)</term><term>Radioimmunodetection</term><term>Receptors, Somatostatin (metabolism)</term><term>Somatostatin (analogs & derivatives)</term><term>Somatostatin (diagnostic use)</term><term>Somatostatin (metabolism)</term><term>Thyroid Neoplasms (metabolism)</term><term>Thyroid Neoplasms (radionuclide imaging)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Immunoglobulin Fab Fragments</term><term>Indium Radioisotopes</term><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Calcitonin</term><term>Carcinoembryonic Antigen</term><term>Receptors, Somatostatin</term><term>Somatostatin</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Carcinoma, Medullary</term><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Carcinoma, Medullary</term><term>Neoplasm Recurrence, Local</term><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Carcinoma, Medullary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Radioimmunodetection</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour characterized by the production and secretion of calcitonin. MTC tumours may express functional somatostatin receptors (hSSTR). A significant proportion of hSSTR receptor-positive MTC tumours, including metastatic disease, may be visualized in vivo through 111In-pentetreotide scintigraphy. Four patients with recurrent/metastatic disease, who had previously been assessed with 111In-anti-CEA monoclonal antibody fragment [F(ab')2] imaging, were evaluated. 111In-pentetreotide scintigraphy localized all known disease sites. Furthermore, mediastinal disease was detected in one patient with negative conventional, and 111In-anti-CEA F(ab')2 imaging studies. The detection of somatostatin within the tumour (2 patients), or negative octreotide challenges (2 patients), did not affect the outcome of 111In-pentetreotide scintigraphy. In conclusion, 111In-pentetreotide scintigraphy appears at least as effective as 111In-anti-CEA F(ab')2 imaging and should be considered in the diagnostic evaluation of MTC, particularly in the setting of recurrent/metastatic disease not detected by conventional means.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8895910</PMID><DateCreated><Year>1997</Year><Month>03</Month><Day>10</Day></DateCreated><DateCompleted><Year>1997</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0143-3636</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>1996</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nuclear medicine communications</Title><ISOAbbreviation>Nucl Med Commun</ISOAbbreviation></Journal><ArticleTitle>Somatostatin and somatostatin analogues in medullary thyroid carcinoma.</ArticleTitle><Pagination><MedlinePgn>810-6</MedlinePgn></Pagination><Abstract><AbstractText>Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour characterized by the production and secretion of calcitonin. MTC tumours may express functional somatostatin receptors (hSSTR). A significant proportion of hSSTR receptor-positive MTC tumours, including metastatic disease, may be visualized in vivo through 111In-pentetreotide scintigraphy. Four patients with recurrent/metastatic disease, who had previously been assessed with 111In-anti-CEA monoclonal antibody fragment [F(ab')2] imaging, were evaluated. 111In-pentetreotide scintigraphy localized all known disease sites. Furthermore, mediastinal disease was detected in one patient with negative conventional, and 111In-anti-CEA F(ab')2 imaging studies. The detection of somatostatin within the tumour (2 patients), or negative octreotide challenges (2 patients), did not affect the outcome of 111In-pentetreotide scintigraphy. In conclusion, 111In-pentetreotide scintigraphy appears at least as effective as 111In-anti-CEA F(ab')2 imaging and should be considered in the diagnostic evaluation of MTC, particularly in the setting of recurrent/metastatic disease not detected by conventional means.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Byrne</LastName><ForeName>K J</ForeName><Initials>KJ</Initials><Affiliation>Department of Endocrinology, St James's Hospital, Dublin, Ireland.</Affiliation></Author><Author ValidYN="Y"><LastName>O'Hare</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Freyne</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Case Reports</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>ENGLAND</Country><MedlineTA>Nucl Med Commun</MedlineTA><NlmUniqueID>8201017</NlmUniqueID><ISSNLinking>0143-3636</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Carcinoembryonic Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Immunoglobulin Fab Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>138661-02-6</RegistryNumber><NameOfSubstance>pentetreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance>Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-12-9</RegistryNumber><NameOfSubstance>Calcitonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Calcitonin</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma, Medullary</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Immunoglobulin Fab Fragments</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radioimmunodetection</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Thyroid Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8895910</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004303 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004303 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:8895910
|texte= Somatostatin and somatostatin analogues in medullary thyroid carcinoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:8895910" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |